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Importing Prescription Drugs from Canada — Legal and Practical
Problems with the Trump Administration’s Proposal
Rachel E. Sachs, J.D., M.P.H., and Nicholas Bagley, J.D.
Importing Prescription Drugs from Canada

A

s Americans report ever-growing difficulty
affording their prescription drugs, President
Donald Trump has come under increasing
pressure to act. To date, the Trump administration
has attempted to advance a number of policy initiatives by means
of executive action, but it has not
yet adopted a program that would
meaningfully assist patients. Most
recently, the administration proposed a rule that, if finalized,
would allow states to develop
programs to import lower-priced
prescription drugs from Canada,
with the intent of reducing spending on drugs by U.S. patients and
states and increasing access for
patients.1
A careful review of the importation proposal, however, suggests
that it is both unlikely to be successful in lowering drug prices
and possibly unlawful. To the extent that it would achieve anything at all, it would do so not by
improving the system for pricing

drugs in the United States, but by
outsourcing the responsibility for
addressing high U.S. drug prices
to Canada. Far from a bold initiative to help people afford their
prescription drugs, the proposal
seems designed to allow the
Trump administration to claim
that it is taking action, even as it
opposes congressional legislation
that would sharply curb some
drug prices.
The legal authority for allowing large-scale importation of prescription drugs from Canada is
not new. In the 2003 law creating
Medicare Part D, Congress authorized such importation — but
“only if the Secretary [of Health
and Human Services (HHS)] certifies to the Congress” that it will
both “pose no additional risk to
n engl j med 382;19

nejm.org

the public’s health and safety”
and “result in a significant reduction in the cost of covered
products to the American consumer.”2 Until now, HHS officials
have been unwilling to make the
required certification, partly because the U.S. Food and Drug
Administration (FDA) could not
ensure the safety of imported
drugs and partly because total
savings attributable to importation would be small.
But policymakers in states as
politically diverse as Vermont,
Florida, Colorado, Maine, and
New Mexico have been pressuring the Trump administration to
permit importation. Each of these
states has passed a law seeking
the flexibility to purchase lowerpriced Canadian medicines for its
residents (see map). In response,
HHS has proposed delegating to
the states the responsibility of
creating their own plans for drug
importation. These state-based importation programs would iden-
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tify a Canadian wholesaler that
buys drugs directly from manufacturers and is willing to sell
those drugs to partners in the
United States. The program would
also have to enlist an American
wholesaler or pharmacy to purchase the drugs from the Canadian wholesaler. With that arrangement in place, a state would
then need to show to HHS’s satisfaction that its plan is likely to
save money and protect patient
safety. If it did so, HHS would
allow the state to conduct a
2-year importation program, subject to future reauthorization.
Having laid out the rules for
state programs, the Trump administration claims that it is now
in a position to make the certification to Congress that the 2003
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law requires. But that claim is a
strange one to make, given that
HHS has not concluded either
that importing drugs would pose
no public health risks or that it
would save money. Rather, HHS
means to issue a kind of conditional certification to Congress:
if a state demonstrates that it can
meet the required conditions,
then the agency will approve the
state’s importation plan.
This approach to importing
drugs from Canada raises at least
three issues regarding legality
and feasibility. First, HHS may
not have the legal authority to
certify to Congress that entirely
hypothetical state plans will save
money and not pose health risks
until the agency has had an opportunity to evaluate them. In-
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deed, HHS acknowledges in the
proposed rule that it is “unable
to estimate the cost savings” at
this point, since potential savings
would depend entirely on the details of states’ importation proposals. Yet certification ought to
come after evaluation, not before
it. As one appeals court has held
in a similar context, “the very
structure of the statute” may preclude the agency from making a
congressional certification in advance of the facts.3
Second, HHS has offered very
limited guidance to the states on
how they might show that importation will reduce costs. In a
terse two paragraphs, the proposal envisions that states could compare the “anticipated acquisition
costs” or the “current retail cash
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price[s]” of drugs in Canada and
the United States. Because prescription drugs are far more expensive in the United States than
they are in Canada — sometimes
many times more expensive —
straightforward price comparisons
would show that importation
would save money.
Such a blunt approach, however, appears certain to yield
wildly inflated savings estimates.
Canadian regulators and the pharmaceutical industry, both of which
oppose the proposal, would not
stand by and watch as drugs are
imported into the United States.
Regulators might change their
rules to discourage exportation,
and the industry might adjust
contractual terms with Canadian
entities that would prevent or at
least deter intermediaries from
partnering with importation programs. In addition, any savings
could accrue to the
An audio interview
wholesalers conductwith Prof. Sachs is
ing the cross-border
available at NEJM.org
sale or to the providers prescribing the imported
drugs, rather than to U.S. patients. Importation might still
save money, at least for some
drugs,4 but a raw comparison of
prices in the United States and
Canada provides very thin support for that conclusion. Pointing
specifically to these types of con-

cerns, the FDA has questioned
“whether this proposed rule could
yield non-zero benefits.”5 The
courts could well put a stop to
such an arbitrary approach to estimating savings.
Third, the proposal asks states
to assemble certain types of information to show that importation
would pose no risks to public
safety, including information on
supply-chain security guarantees
and testing requirements. But it is
perplexing that the federal government would ask states to gather and submit information that
the FDA has already collected. It
may not even be possible for
states to gather the requested information — indeed, the proposal
explicitly acknowledges that states
“may not know whether” a drug
they propose to import meets the
FDA’s requirements.
The administration’s proposal
is thus both puzzling from a policy standpoint and legally dubious. At least some of these problems could have been avoided if
the Trump administration had
moved to adopt its own importation program, as the 2003 law
seemingly contemplates.
So why punt to the states? As
with several of the administration’s other executive actions on
drug pricing, the proposal appears to be political theater, de-

signed to mollify the public and
restive states without overly antagonizing the pharmaceutical industry. But the Trump administration should get no credit for a
step of questionable legality that
will not help the vast majority of
Americans afford their prescription drugs — especially because
it has rejected reform proposals
from states that drew the concentrated ire of drug manufacturers.
If states and the American
public want lower drug prices,
this proposal won’t help. They
will need to push the federal
government to do more than pay
lip service to the urgent need to
constrain spending on prescription drugs.
Disclosure forms provided by the authors
are available at NEJM.org.
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Implementing the Cures Act — Bringing Consumer Computing
to Health Care
Donald W. Rucker, M.D.

S

martphones and electronic
transparency have transformed
our lives and the U.S. economy.
Yet health care remains a stark
exception. When health informa-

tion is available, it tends to be
accessible only in ways that bind
patients to their current health
care providers and insurance
plans. Medical and cost informa-
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tion is far more helpful if patients
can use it on their own terms,
with tools of their own choosing.
In the decades since the passage
of the Stabilization Act of 1942
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